MerusMRUS
MRUS
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
36% more call options, than puts
Call options by funds: $5.1M | Put options by funds: $3.75M
33% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 54
19% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 31
8% more funds holding in top 10
Funds holding in top 10: 12 [Q3] → 13 (+1) [Q4]
2% more funds holding
Funds holding: 188 [Q3] → 192 (+4) [Q4]
1.59% more ownership
Funds ownership: 101.2% [Q3] → 102.79% (+1.59%) [Q4]
14% less capital invested
Capital invested by funds: $3.45B [Q3] → $2.96B (-$494M) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$70
77%
upside
Avg. target
$86
118%
upside
High target
$109
175%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
Guggenheim Michael Schmidt 29% 1-year accuracy 10 / 35 met price target | 175%upside $109 | Buy Reiterated | 28 Mar 2025 |
B of A Securities Tazeen Ahmad 26% 1-year accuracy 9 / 34 met price target | 77%upside $70 | Buy Maintained | 10 Mar 2025 |
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 113 / 357 met price target | 115%upside $85 | Buy Reiterated | 3 Mar 2025 |
Needham Ami Fadia 29% 1-year accuracy 50 / 171 met price target | 110%upside $83 | Buy Maintained | 28 Feb 2025 |
Piper Sandler Joseph Catanzaro 36% 1-year accuracy 9 / 25 met price target | 112%upside $84 | Overweight Initiated | 13 Feb 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
14 hours ago
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025 at 8:45 a.m. ET.
Negative
Zacks Investment Research
1 month ago
Merus N.V. (MRUS) Reports Q4 Loss, Lags Revenue Estimates
Merus N.V. (MRUS) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to loss of $1.09 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update
- Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially enrolled by YE25
Neutral
GlobeNewsWire
1 month ago
Merus to Present at Upcoming Investor Conferences
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
Neutral
GlobeNewsWire
1 month ago
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
Neutral
GlobeNewsWire
1 month ago
Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
Neutral
GlobeNewsWire
1 month ago
New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the New England Journal of Medicine (NEJM) published results of the registrational phase 2 eNRGy trial for Bizengri® (zenocutuzumab), the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung cancer (NSCLC) that are advanced unresectable or metastatic and harbor a neuregulin 1 (NRG1) gene fusion who have disease progression on or after prior systemic therapy.
Positive
Seeking Alpha
2 months ago
Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff
Bizengri's recent approval gives MRUS the first approved therapy for NRG1+ cancers, which, I think, will be a valuable niche. Petosemtamab's recent Phase 2 data for HNSCC suggests it could also have blockbuster potential as long as its Phase 3 trials are successful as well. I also like MRUS's recent partnership with BHVN as it gives it optionality with new ADC programs that could have oncology applications.
Neutral
GlobeNewsWire
2 months ago
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
NEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Biohaven Ltd. (NYSE: BHVN) and Merus N.V. (Nasdaq:MRUS), today announced a research collaboration and license agreement to co-develop three novel bispecific antibody drug conjugates (ADCs), leveraging Merus' leading Biclonics® technology platform, and Biohaven's next-generation ADC conjugation and payload platform technologies.
Neutral
GlobeNewsWire
3 months ago
Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®) for cancer, today announced that the first patient has been dosed in the Company's phase 2 trial evaluating petosemtamab monotherapy in heavily pretreated (3L+) metastatic colorectal cancer (mCRC). Petosemtamab is a Biclonics® targeting EGFR and LGR5.
Charts implemented using Lightweight Charts™